TICKERNERD
Menu
RGENRGENHealthcare · Medical Instruments & Supplies

RGEN Stock Forecast: Repligen Corp. Price Predictions for 2026-2027

Last close, 25 Aug 2026
$182
+0.04% on the day

The 22 Wall Street analysts covering Repligen Corp. hold a median 12-month price target of $185 — +1.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 24 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$10.2B
Ticker Nerd rank
91 / 100
Median analyst target
$185
Analysts covering
22
Revenue$204.1M+11.9% y/y
Operating income$19.0M
Net income$5.0M
Free cash flow$26.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+9.4%
1M
+37.7%
YTD
+10.9%
1Y
+49.8%
From 52W high
0.0%
From 52W low
+76.6%
$103
$182
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RGEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Repligen Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 24 Aug 2026
91 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
89
Quality
81
Growth
80
Momentum
75
Volatility
74
Value
71
Accruals
65
Issuance
57
Size
15

Revisions (89): Analysts have, on balance, been raising their forecasts.

Issuance (57): The company has been issuing shares or taking on financing, diluting existing holders.

Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$120$140$160$180$200$220Oct 25Jan 26Apr 26Jul 26RGENHigh $220Median $185Low $145

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
18 Buy4 Hold0 Sell
Low $145Median $185High $220

The green dot is the last close — the median target sits +1.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 July 2026Wells FargoMaintainsOverweight$180 → $185
29 July 2026JP MorganMaintainsOverweight$165 → $175
7 July 2026BenchmarkUpgradeBuy—
7 July 2026BenchmarkUpgradeBuy$185
6 July 2026Evercore ISI GroupMaintainsOutperform—
6 July 2026Evercore ISI GroupMaintainsOutperform$150 → $160
3 June 2026HSBCMaintainsBuy—
2 June 2026Wolfe ResearchAssumesOutperform$145
15 May 2026RBC CapitalReinstatesOutperform$160
6 May 2026BarclaysMaintainsOverweight—
6 May 2026JP MorganMaintainsOverweight—
20 Apr 2026Canaccord GenuityMaintainsHold—
17 Apr 2026Roth CapitalInitiatesBuy—
14 Apr 2026BarclaysMaintainsOverweight—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
23 Mar 2026HC Wainwright & Co.MaintainsBuy—
25 Feb 2026BarclaysMaintainsOverweight—
25 Feb 2026Evercore ISI GroupMaintainsOutperform—
25 Feb 2026UBSMaintainsBuy—
25 Feb 2026Wells FargoMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RGEN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RGEN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 25 Aug 2026, Repligen Corp. returned +49.8% against +20.5% for the S&P 500, dividends included.

RGEN vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Oct 25Jan 26Apr 26Jul 26RGENS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.2%
Analysts raising
20
Analysts cutting
0
Fundamentals

Repligen Corp. (RGEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
248.8×

Cheaper than 3% of US stocks

Price / sales
13.1×

Cheaper than 12% of US stocks

Price / book
4.9×

Cheaper than 23% of US stocks

EV / EBITDA
70.3×

Cheaper than 3% of US stocks

Growth & margins
Revenue growth (YoY)
11.9%

Higher than 57% of US stocks

Earnings growth (YoY)
−66.3%

Higher than 7% of US stocks

Gross margin
53.9%

Higher than 67% of US stocks

Operating margin
9.3%

Higher than 63% of US stocks

Net margin
5.3%

Higher than 60% of US stocks

Returns & dividend
Return on equity
2.0%

Higher than 47% of US stocks

Return on assets
1.4%

Higher than 54% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Repligen Corp. (RGEN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Repligen Corp. has a market value of $10.2B and an enterprise value of $10.1B.

  • Revenue in the twelve months to 30 June 2026: $785.1M. The latest quarter grew 11.9% year on year.

  • Net income over the same four quarters: $41.5M, a 5.3% net margin.

  • Diluted earnings per share, trailing twelve months: $0.73.

  • Free cash flow in the twelve months to 30 June 2026: $110.2M, after $1.8M of capital spending.

  • Shares outstanding: 56.4M.

  • Trailing P/E: 248.8×; forward P/E: 68.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Repligen Corp. employs 2,000 people — $393K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

RGEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
RGENRepligen Corp.$10.2B
91
AVTRAvantor, Inc.$9.7B
80
ALGNAlign Technology, Inc.$11.5B
81
ATRAptarGroup, Inc.$8.8B
47
BAXBaxter International, Inc.$13.6B
89
COOThe Cooper Cos., Inc.$14.9B
79
SOLVSolventum Corp.$15.8B
90

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Repligen Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RGEN news & analysis

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.

24/7 Wall Street · 25 Aug 2026neutral

On August 19, 2026, Merck and Moderna reported positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy combined with Keytruda in resected melanoma. The news lifted five biotech names, with the article assessing which companies are best positioned.

Why it matters — Positive Phase 3 results in personalized cancer vaccines could signal broader growth in the oncology/bioprocessing space, an area relevant to Repligen's cell culture and bioprocessing business.

Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade

Zacks Investment Research · 30 July 2026neutral

Zacks Investment Research reported that the consensus price target for Repligen (RGEN) suggests a 25.7% upside potential, while also noting that upward earnings estimate revisions could indicate near-term upside for the stock.

Why it matters — A RGEN watcher would care because analyst price targets and earnings estimate revisions are among the signals investors watch for potential stock movement.

Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up

Zacks Investment Research · 29 July 2026positive

Repligen Corp. beat Q2 earnings and revenue estimates, raised its 2026 revenue and EPS outlook, and saw its stock jump after stronger-than-expected results.

Why it matters — An earnings beat and an upward revision to the 2026 outlook suggest improving financial momentum, which RGEN watchers would see as a positive signal for the company's performance trajectory.

Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 28 July 2026neutral

Seeking Alpha published the transcript of Repligen Corporation's Q2 2026 earnings call.

Why it matters — The transcript provides RGEN watchers with management's full discussion of quarterly results and business conditions.

Repligen Q2 Earnings Call Highlights

MarketBeat · 28 July 2026positive

Repligen reported second-quarter 2026 revenue of $204 million, up 12% year over year, and raised its full-year organic revenue growth and adjusted earnings outlook due to continued order momentum and improved visibility.

Why it matters — The raised full-year outlook signals strengthening demand for Repligen's core protein, analytics and consumables products, which is a key indicator for the company's near-term growth trajectory.

FAQ

Frequently asked questions about RGEN stock

What is the RGEN stock price forecast for 2026-2027?

The 22 Wall Street analysts covering Repligen Corp. have a median 12-month price target of $185, with estimates ranging from $145 to $220. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RGEN stock a buy right now?

Of the 22 analysts covering Repligen Corp., 18 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Repligen Corp. 91 out of 100 across roughly 4,600 US stocks as at 24 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RGEN?

As at 24 Aug 2026, Repligen Corp. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (89 of 100).

Will RGEN stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +1.8% from the last close, and Ticker Nerd's factor model ranks Repligen Corp. 91 out of 100 as at 24 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RGEN stock forecast for 2030?

No analyst covering Repligen Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $145 to $220 over the next 12 months.

How has RGEN stock performed over the past year?

Repligen Corp. returned +49.8% over the 12 months to 25 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Repligen Corp. do?

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems to support the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Headquartered in Waltham, Massachusetts, it serves biopharmaceutical drug developers, contract development and manufacturing organizations (CDMOs), and other life science companies across North America, Europe, and Asia Pacific.

What is the latest news on RGEN?

The most recent item we track (24/7 Wall Street, 25 Aug 2026): "Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.". On August 19, 2026, Merck and Moderna reported positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy combined with Keytruda in resected melanoma. The news lifted five biotech names, with the article assessing which companies are best positioned.

Company

About Repligen Corp.

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems to support the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Headquartered in Waltham, Massachusetts, it serves biopharmaceutical drug developers, contract development and manufacturing organizations (CDMOs), and other life science companies across North America, Europe, and Asia Pacific. The company offers products in four main categories: filtration and fluid management, its largest segment; chromatography, including OPUS pre-packed columns and high-performance resins like AVIPure HiPer for viral vectors; proteins, such as Protein A ligands and affinity chromatography components; and process analytics, featuring slope spectroscopy systems like SoloVPE and FlowVPE. Repligen's technologies enable purification, cell culture growth, and process monitoring, addressing key needs in biologics production for next-generation modalities like gene therapy.

CEO Mr. Olivier Loeillot · 2,000 employees · United States · https://www.repligen.com